HERON THERAPEUTICS, INC. /DE/ - 8-K Filing
On June 2, 2026, Heron Therapeutics announced that the U.S. District Court for Delaware ruled its patents (Nos. 12,115,255 and 12,290,520) covering CINVANTI® are invalid after a bench trial with Azurity Pharmaceuticals. The decision does not affect prior settlement agreements related to CINVANTI or APONVIE® injectable emulsions. Heron plans to appeal the ruling to the U.S. Court of Appeals for the Federal Circuit. (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $HRTX